There is growing evidence that Ozempic and other GLP-1 receptor agonist drugs might help people drink less alcohol, but more research is needed.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Novo Nordisk NVO shares have gained 13.9% in the past month. Several factors related to the company’s pipeline, regulatory ...

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in ...

Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second ...

How Does Semaglutide Work for Weight Loss? This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Ozempic. Wegovy. Rybelsus. What do these medications have in common? They all contain ...

Participants treated with semaglutide also saw improvements in liver enzymes and blood measures of liver fibrosis, as well as 10.5% weight loss. "I've been working with GLP-1 treatments for 16 ...

Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group. The Food and Drug Administration (FDA) has accepted for review ...

How Long Does It Take for Semaglutide to Work? This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Semaglutide is the active ingredient in the weight loss medication Wegovy and the ...

Under the brand name Wegovy (Novo Nordisk), semaglutide was approved for chronic weight management in 2021, 2 and as Zepbound (Eli Lilly), tirzepatide was approved for the same indication in 2023.